Side effects of acalatinib/acalatinib targeted drugs

Acalabrutinib/Acalabrutinib is a targeted therapy drug used to treat some blood cancers, such as adult chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (SLL) and mantle cell lymphoma (MCL). However, there may be some side effects from using this medication.

According to clinical study results of acotinib, forMCL patients, the most common side effects include anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia and bruising. For patients with CLL or SLL, joint pain, dizziness, and constipation are also common side effects. In addition, there is a risk of serious side effects and potential infection during the use of acalabrutinib/acalabrutinib. These serious side effects include serious and opportunistic infections, bleeding, cytopenias, second primary malignancies, atrial fibrillation and flutter. If these warning signs occur, it is recommended to stop using the drug and reduce the dose appropriately after recovery or permanently discontinue use. The specific treatment method should be determined based on the severity of the side effects.

For patients taking acalabrutinib/acalabrutinib, the most important thing is to pay close attention to changes in their bodies and communicate with their doctors in a timely manner. Doctors will assess the effectiveness of treatment and the risk of side effects on a patient-specific basis so that appropriate measures can be taken to manage side effects and ensure the safety of the treatment.

In short, acalabrutinib/Acalabrutinib is an effective targeted therapy, but some side effects may occur during use. Understanding these side effects and working closely with your doctor will help maximize the effectiveness of the medication and ensure patient safety.